Search results for "Beta blocker"

showing 10 items of 12 documents

The influence of penbutolol and placebo on blood sugar levels and insulin consumption in the glucose-controlled insulin infusion system ("artificial …

1990

The aim of the study was to investigate the influence of 40 mg of the beta-blocker penbutolol (Betapressin TM; Hoechst Ltd., Frankfurt/Main) in comparison to placebo on the insulin consumption on the blood sugar profile in twelve insulin-dependent diabetes (IDDM) patients. The patients were treated with penbutolol and placebo for a period of three days, and then were examined with the help of the glucose-controlled insulin infusion system. The blood sugar profile and insulin consumption over a 24 hour period was not affected by either penbutolol or placebo, nor could any changes be measured in these parameters when measured after food intake. After a submaximal exercise load on the bicycle …

AdultBlood GlucoseMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentBlood sugarPhysical exercisePlaceboPlacebosCatecholaminesInsulin Infusion SystemsPenbutololDiabetes mellitusInternal medicineDrug DiscoverymedicineHumansInsulinBeta blockerExerciseGenetics (clinical)Artificial endocrine pancreasbusiness.industryInsulinGeneral Medicinemedicine.diseaseHormonesEndocrinologyDiabetes Mellitus Type 1Molecular MedicineFemalePenbutololbusinessmedicine.drugKlinische Wochenschrift
researchProduct

Cardiovascular medication and intraocular pressure: results from the Gutenberg Health Study

2016

BACKGROUND Intraocular pressure (IOP) is well known to be associated with blood pressure and other cardiovascular risk factors. The influence of systemic cardiovascular, in particular antihypertensive, medication on IOP is still controversial. This study analyses the association between the use of cardiovascular medications and IOP in a large European cohort. METHODS The Gutenberg Health Study is a population-based, prospective,observational cohort study in mid-western Germany. IOP was measured using a non-contact tonometer. The medication classes examined were peripheral vasodilators, diuretics, β-blockers (overall, selective and non-selective), calcium channel blockers, renin-angiotensin …

AdultMaleIntraocular pressureTime Factorsgenetic structuresmedicine.drug_classHealth StatusBlood Pressure030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineRisk FactorsGermanyPrevalenceHumansMedicineProspective Studies610 Medicine & healthBeta blockerIntraocular PressureAgedAspirinbusiness.industryCARDIOVASCULAR MEDICATIONSCardiovascular AgentsMiddle AgedPrognosiseye diseasesSensory SystemsOphthalmologyBlood pressureCardiovascular DiseasesPopulation SurveillanceAnesthesiaCohort030221 ophthalmology & optometryFemaleOcular Hypertensionsense organsbusinessBody mass indexFollow-Up StudiesCohort studymedicine.drugBritish Journal of Ophthalmology
researchProduct

Transmural myocardial ischaemia complicating recovery after dobutamine-atropine stress echocardiography in patients with non-significant coronary art…

2011

In the proposed selection of cases, traditional imaging is integrated with contemporary diagnostic tools available in the cath-lab to navigate the potential mechanisms underlying a very rare complication occurring in the recovery phase of dobutamine-atropine stress echocardiography. The data, collected in a time frame of nearly 15 years, provide interesting elements to possibly evolve from speculative considerations to plausible confirmation of the candidate pathophysiological mechanism mediating the occurrence of transmural myocardial ischaemia after beta-blockers administration.

AtropineMaleChest Painmedicine.medical_specialtyMyocardial ischaemiamedicine.drug_classAdrenergic beta-AntagonistsMyocardial IschemiaCoronary Artery DiseaseCoronary AngiographyCoronary artery diseaseElectrocardiographyInternal medicineStress EchocardiographyHumansMedicineRadiology Nuclear Medicine and imagingBeta blockerAgedbusiness.industryParasympatholyticsGeneral MedicineMiddle Agedmedicine.diseaseFractional Flow Reserve MyocardialAtropineCardiologyFemaleDobutamineCardiology and Cardiovascular MedicinebusinessComplicationCoronary physiologyEchocardiography Stressmedicine.drugEuropean Journal of Echocardiography
researchProduct

Heart rate control with oral ivabradine in computed tomography coronary angiography: a randomized comparison of 7.5 mg vs 5 mg regimen.

2013

Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of oral ivabradine seems to be more effective than beta-blockade in reducing HR in patients referred for CTCA. Methods: Two-hundred-fifty-nine consecutive patients referred for CTCA were prospectively enrolled. Patients not receiving beta-blocker at baseline (group 1) and those with beta-blocker therapy (group 2) were enrolled in the study. Each group was randomized into 3 parallel arms with 1:1:1 allocation. Patients who did not receive beta-blocker at baseline: underwent CTCA without beta blocker (n=49), and receiv…

Coronary angiographyMalemedicine.medical_specialtymedicine.drug_classAdministration OralComputed tomographyCoronary Artery DiseaseCoronary AngiographyComputed tomography coronary angiographyCohort StudiesHeart RateInternal medicineHeart ratemedicineHumansIvabradineProspective StudiesHeart rate reductionBeta blockerDose ModificationAgedRetrospective Studiesmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryBenzazepinesMiddle AgedCoronary heart diseaseRegimenBlood pressureAnesthesiaCardiologyFemaleCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedIvabradinemedicine.drug
researchProduct

Multicentric study on the beta-blocker use and relation with exacerbations in COPD

2014

SummaryChronic obstructive pulmonary disease (COPD) is frequently associated with chronic heart failure (CHF) or coronary artery disease (CAD). In spite of the recommendation to use beta-blockers (BB) they are likely under-prescribed to patients with concurrent COPD and heart diseases. To find out the prevalence of use of BB, 256 COPD patients were consecutively recruited by pulmonary physicians from 14 hospitals in 7 regions of Spain in their outpatient offices if they had a diagnosis of COPD, were not on long-term oxygen therapy, had CHF or CAD, and met the criteria for BB treatment.In patients with indication 58% (95%CI, 52–64%) of the COPD patients and 97% of the non-COPD patients were …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPopulationAdrenergic beta-AntagonistsComorbidityCoronary Artery DiseaseEmergency treatmentSeverity of Illness IndexCoronary artery diseasePulmonary Disease Chronic ObstructiveRisk FactorsInternal medicineDiabetes mellitusOxygen therapymedicineHumansMyocardial infarctioneducationBeta blockerAgedAged 80 and overHeart Failureeducation.field_of_studyCOPDbusiness.industryAdverse effectsChronic obstructive pulmonary diseaseMiddle Agedmedicine.diseaseDrug UtilizationBronchodilator AgentsMyocardial infarctionCross-Sectional StudiesSpainHeart failureCardiologyFemalebusinessEmergency Service HospitalRespiratory Medicine
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.

2016

OBJECTIVE To assess the association between early and prolonged beta blocker treatment and mortality after acute myocardial infarction. DESIGN Multicentre prospective cohort study. SETTING Nationwide French registry of Acute ST- and non-STelevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005. PARTICIPANTS 2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction. MAIN OUTCOME MEASURES Mortality was assessed at 30 days in relation to early use of beta blockers (<= 48 hours of admission), at one year in relation to discharge prescription, and at five years in relation to one year use. RESULTS beta blockers were…

MaleTime FactorsMyocardial Infarction030204 cardiovascular system & hematologyCorrectionsCohort Studies0302 clinical medicineMedicine030212 general & internal medicineMyocardial infarctionProspective StudiesProspective cohort studyHazard ratioGeneral MedicineMiddle AgedMetaanalysisPatient Discharge3. Good healthManagementImpactAcute DiseaseCardiologyFemaleLife Sciences & Biomedicinemedicine.medical_specialtyRegistrySt-Segment-Elevationmedicine.drug_classAdrenergic beta-AntagonistsGuidelines03 medical and health sciencesMedicine General & InternalFast-MiInternal medicineGeneral & Internal Medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyClinical-OutcomesHumansBeta blockerSurvival analysisAgedProportional Hazards ModelsHeart FailureScience & Technologybusiness.industryProportional hazards modelResearchCoronary Care Unitsmedicine.diseaseSurvival AnalysisDiscontinuationLogistic ModelsAdherenceHeart failureTherapybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBMJ (Clinical research ed.)
researchProduct

Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal bac…

2013

Background The organic nitrate pentaerithrityl tetranitrate (PETN) has been shown to have ancillary properties that prevent the development of tolerance and endothelial dysfunction. This randomized, double-blind, placebo-controlled, multicentre study (‘CLEOPATRA’ study) was designed to investigate the anti-ischaemic efficacy of PETN 80 mg b.i.d. (morning and mid-day) over placebo in patients with chronic stable angina pectoris. Methods and results A total of 655 patients were evaluated in the intention-to-treat population, randomized to PETN (80 mg b.i.d., n = 328) or placebo ( n = 327) and completed the study. Patients underwent treadmill exercise tests at randomization, after 6 and 12 wee…

Malemedicine.medical_specialtyRandomizationmedicine.drug_classVasodilator AgentsPopulationAdrenergic beta-AntagonistsPlacebo-controlled studyPlaceboAdrenergic beta-AntagonistsMedication AdherenceDouble-Blind MethodmedicineClinical endpointHumansPentaerythritol TetranitrateAngina StableEndothelial dysfunctioneducationBeta blockereducation.field_of_studyExercise Tolerancebusiness.industryMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaDelayed-Action PreparationsChronic DiseaseExercise TestFemaleCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Accumulation and Adverse Effects of Metoprolol and Propranolol After Concurrent Administration of Cimetidine

1983

Pharmacokinetics of metoprolol, propranolol and atenolol were investigated in six healthy volunteers following 7 days of oral monotherapy with these drugs and after 7 days concurrent administration of each of these betareceptor antagonists with cimetidine. Application of cimetidine did not lead to any interaction with atenolol, whereas mean peak plasma levels of metoprolol were increased by 70%, and those of propranolol by 95% due to concurrent administration of cimetidine (p < 0.05). The AUC of the two last mentioned beta blockers behaved similarly (p < 0.05). Measurement of exercise-induced tachycardia on the 6th day of administration showed no differences between monotherapy with the bet…

medicine.drug_classbusiness.industryPropranololPharmacologyDrug interactionAtenololPharmacokineticsmedicineCimetidinebusinessBeta blockerVolunteermedicine.drugMetoprolol
researchProduct

A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone

2018

Key Teaching Points • Despite proven catecholaminergic polymorphic ventricular tachycardia (CPVT) with pathogen RyR2 mutation and recurrent syncope, patients could have a favorable long-term outcome over 35 years under treatment. • Propafenone could be effective for treatment of patients with CPVT. • The beneficial effect of the monotherapy with propafenone in our patient may result from the combined antiarrhythmic effect of this drug with Na+ channel blockade and beta blocker capabilities.

medicine.medical_specialtyPolymorphic premature ventricular beatsmedicine.drug_classCase ReportPropafenone030204 cardiovascular system & hematologyCatecholaminergic polymorphic ventricular tachycardiaRyanodine receptor 203 medical and health sciences0302 clinical medicinePropafenoneInternal medicineMedicineEffective treatment030212 general & internal medicineExercise-induced syncopeBeta blockerbusiness.industrymedicine.diseaseBlockadeExercise-induced syncopeCatecholaminergic polymorphic ventricular tachycardiacardiovascular systemCardiologyAntiarrhythmic effectCardiology and Cardiovascular MedicinebusinessRyanodine receptor mutationmedicine.drugHeartRhythm Case Reports
researchProduct